Tagged with ipha

UAE Mundipharma, through its model of independent associated companies, is aiming to take the lead in the Middle East, Turkey & Africa markets through its continuous commitment to improving peoples’ lives. Ashraf Allam, regional VP for the META region, discusses his journey of building Mundipharma’s strong footprint in the region and…

Sweden Since going public five years ago, Recipharm, Sweden’s iconic indigenous contract development and manufacturing organization (CDMO), has seen its sales skyrocket by over 30 percent annually. Much of this growth has been driven by an acquisition streak with the company plucking up overseas production assets such as former Roche and…

Sweden Thomas Eldered, CEO of Sweden’s largest CDMO Recipharm, founded the company together with his business partner in 1995. Since becoming a public company in 2014, he highlights how this changed the business model and created a pure CDMO whilst increasingly expanding its global footprint both organically and through acquisitions in…

Thailand Suchart Chookruvong and Wanna Thanesanont of Thai generics player Polipharm, highlight the growing importance of R&D within their strategy, how the firm has remained focused on quality, and why Polipharm aims to position itself as the partner of choice for all stakeholders in Thailand; a local company with an international…

Spain Javier Alvarado, general manager of Mundipharma Spain, discusses his current priorities and the innovation the company is bringing to the market through a diversified portfolio. Furthermore, he points out the importance of long-term strategic partnerships for the company´s success and his future aspirations for the affiliate.   Of course, none…

Portugal Salvador Lopez saw an opportunity in the summer of 2015 to create the first Portuguese affiliate for Mundipharma. Three years on, he reveals how their business model, company culture and leadership has succeeded in disrupting the respiratory market with their blockbuster drug Flutiform, built the fastest growing subsidiary in Portugal…

Tunisia Walid Chriaa, CEO of SIPHAT, explains the history of the public company’s position in Tunisia, as the pearl of the Tunisian pharmaceutical industry. He also points out a few of the strategies in place to counter the financial struggles that SIPHAT has been under, such as reforms with a 2030…

Colombia With Latin America’s best healthcare system in terms of both coverage and quality, Colombia is fast becoming a destination of choice for multinationals, not only to set up shop in the sense of establishing a direct local affiliate, but also for opening regional headquarters and implanting managerial functions. “We are…

Colombia David Leclercq, general manager of Mundipharma Colombia, reveals his passion for both the Colombian affiliate and the welfare of the Colombian people and gives insight into operating a new pharmaceutical outfit in a highly transformative healthcare environment. You were appointed General Manager in Colombia back in 2014; what have been…

Indonesia Mada Shinta Dewi, country manager at Mundipharma Indonesia, explains the unique business model of Mundipharma in Indonesia, collaboration with the local business community, and the benefits that the company’s consumer health medicines and ethical business line can bring to patients. Could you please explain to our international audience how the…

Taiwan Terry Lin, general manager, and Freia Wei, director for international business at UniPharma, on the company’s move from specialty distribution to drug development and diagnostic products. With an upcoming IPO, UniPharma is considering both organic and inorganic development opportunities to further nurture its geographical expansion. Being one of the best-established…

Mexico Francisco Rodriguez, general manager Mexico and Latin America at Mundipharma, provides an overview of the customized market approach that has allowed the company to establish itself as the partner of choice of the medical and regulatory authorities in the pain management field, and how Mundipharma now looks at replicating similar…